ABOUT US
NEWS
EVENTS
MEDIA ROOM
SURVEILLANCE DATA
CONTACTS
SITE MAP
Copyright © 2007 The Network for Surveillance of Pneumococcal Disease in the East African Region . All rights reserved.

data as consolidated by Netspear

Data collected from the various PBM/netSPEAR surveillance sites in East Africa present a noteworthy trend in the cause of Hib disease. Since the initiation of the network surveillance, samples of CSF and Blood Cultures (BC) have been collected from the various sites and isolates are sometimes sent to the referral labobratory in Kilifi, Kenya for serotyping and confirmation of the isolates reported.

The links below give way to illustrated charts/graphs of the number of samples collected and the data of isolates reported from the surveillance sites but have not necessarily been confirmed at the referral laboratory. Most of the data given is over the period from August 2003 to December 2007.

  1. Cummulative data and monthly totals of CSF and BC samples collected from the sites

  2. Number of S. pneumoniae (SPN), H. influenzae (HIN) and N.meningitidis (NME) collected from CSF in the four countries since initiation of surveillance.

  3. Number of S. pneumoniae (SPN), H. influenzae (HIN) and N.meningitidis (NME) collected from BC in Kenya and Uganda since initiation of surveillance.

  4. A comparison of the proportions of S. pneumoniae (SPN), H. influenzae (HIN) and N.meningitidis (NME) in the Hib Vaccine countries and Non-Hib Vaccine countries.

  5. Cumulative data showing the total number of lab confirmed SPN and HIN isolates and the total number of S. pneumoniae (SPN), H. influenzae (HIN) sent in for confirmation.
DEFINING THE PHENOTYPIC CHARACTERISTICS OF PNEUMOCOCCI

SPN is an important cause of morbidity and mortality. There are 91 recognized serotypes of SPN, a few which are vaccine preventable. The isolation of SPN continues to be a challenge. Continued surveillance, description of the serotypes and antibiotic resistance profiles of the isolates in the E. African region will help in the determination of appropriate vaccine and treatment regiments.  A total of 442/495 from 13 sites in E. Africa were reconfirmed as SPN, serotyped and MIC determined at the coordinating lab in Kilifi. More >>

USE OF PENTAVALENT VACCINE & SURVEILLANCE RESULTS
Surveillance Results

The introduction of the pentavalent vaccine has seen significant reduction of Hib disease in the uptake countries. The effectiveness of the Hib vaccine has been demonstrated through enhanced surveillance in the East African region through studies such as 'Uganda Hib Vaccine Effectiveness Study' and 'Kenyan Study to define incidence of invasive Hib disease'. More >>